New clinical trial results for
heart transplant patients will be released at the upcoming International
Society for Heart and Lung Transplantation (ISHLT) 27th Annual Meeting and
Scientific Sessions at the Hilton San Francisco, April 25-28, 2007. Results
show promise for efficacy and safety of immunosuppression therapy and lower
incidences of acute organ rejection in heart transplants.
Research to be presented includes:
-- Six Month Data on Cyclosporine Reduction and Impact on Renal Function
with Everolimus In De Novo Heart Transplant Recipients will be
presented Wednesday, April 25 during a luncheon symposium at 12:30pm
PDT.
-- 6 Month Data from a 12 Month Study of Everolimus with Reduced
Cyclosporine Exposure vs. MMF and Conventional Cyclosporine in De Novo
Heart Transplant Recipients will be presented during the same luncheon
symposium on April 25.
The leading cause of death during the first year following heart
transplant is acute rejection of the transplanted organ. The patient's
immune system attacks the heart as if it were a foreign object until it no
longer functions properly. The one-year survival rate after transplantation
is approximately 80 percent; this number drops to nearly 50 percent after
10 years.
About ISHLT
The International Society for Heart and Lung Transplantation (ISHLT) is
a not-for-profit organization dedicated to the advancement of the science
and treatment of end-stage heart and lung diseases. Created in 1981, the
Society now includes more than 2,200 members from 45-plus countries,
representing a variety of disciplines involved in the management and
treatment of end-stage heart and lung disease.
ISHLT manages two vital databases. The International Heart and Lung
Registry is a one-of-a-kind registry that has been collecting data since
1983 from 223 hospitals from 18 countries. The ISHLT Mechanical Circulatory
Device (MCSD) database has been collecting data since 2002 with the aim of
identifying patient populations who may benefit from MCSD implantation,
generating predictive models for outcomes; and assessing the mechanical and
biological reliability of current and future devices. In Fall 2006, ISHLT
released the first international guidelines for heart failure patient
management. For more information, visit ishlt.
International Society for Heart and Lung Transplantation
ishlt